References
- Peter JG, Neil H, Dennis LK, et al. Migraine and other Primary Headache Disorders. Principles of Internal Medicine. New York: Mc Graw Hill, 2016; p. 2586-2598.
- Steiner TJ, Stovner LJ, Birbeck GL. Migraine: the seventh disabler. Cephalalgia. 2013;33:289-290.
- Steiner TJ, Stovner LJ, Vos T. Migraine is the third cause of disability in under 50s. J Headache Pain. 2016;17:4.
- Blumenfeld AM, Varon SF, Wilcox TK. HRQoL and resource use among chronic and episodic migraineures: results from the International Burden of Migraine Study (IBMS). Cephalalgia. 2011;31:301-315.
- Headache Classification Committee of the International Headache society (IHS). The International Classification of Headache Disorders. Cephalalgia. 2013;33:629-808.
- Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache. 2008;48:1157-1168.
- Stewart WF, Lipton RB, Whyte J, et al. An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score. Neurology. 1999;53:988-994.
- Kelman L. The triggers or precipitants of the acute migraine attack. Cephalalgia. 2007;27:394-402.
- Banday MS, Wani M, Para BA, Qureshi S. Impact of trigger factors on clinical profile of migraine patients. Int J Basic Clin Pharmacol. 2020;9:1191.
- Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38:1–211.
- Pooja Mohan Rao. Diagnosis and Treatment of Migraine. Journal of Clinical Outcomes Management. 2017;24:516-526.
- Diener HC, Dodick DW, Aurora SK, et al. Onabotulinumtoxin A for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30:804-814.
- Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:1337-1345.
- Scottish Intercollegiate Guidelines Network (SIGN). Pharmacological management of migraine. Edinburgh: SIGN; 2022. https://www.sign.ac.uk/our-guidelines/pharmacological-management-of-migraine/ (15 February 2022)
- Linde M, Mulleners WM, Chronicle EP, McCrory DC. Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev. 2013;6:CD010611.